{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["32(12)"],"submitter":["Bongiovanni A"],"pubmed_abstract":["Renal Cell Carcinoma (RCC) is a common malignancy, often diagnosed incidentally. In recent years, the prognosis of metastatic disease has been improved due to the development of immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI) as first-line treatments. However, when progression occurs, the therapeutic options are limited. Understanding crucial biological pathways could lead to a greater understanding of the natural history of the disease, which could help to overcome the mechanism of resistance and to develop new treatments. The clinical significance of homologous recombination deficiency (HRD) in RCC remains to be investigated. To improve the knowledge about this topic, we conducted a narrative review to summarize the current evidence on HRD-related variations and s"],"journal":["Current oncology (Toronto, Ont.)"],"pagination":["690"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12731853"],"repository":["biostudies-literature"],"pubmed_title":["The Role of Homologous Recombination Deficiency (HRD) in Renal Cell Carcinoma (RCC): Biology, Biomarkers, and Therapeutic Opportunities."],"pmcid":["PMC12731853"],"pubmed_authors":["Cognetti F","Landriscina M","Conteduca V","Bongiovanni A","Conte P","Di Lorenzo G"],"additional_accession":[]},"is_claimable":false,"name":"The Role of Homologous Recombination Deficiency (HRD) in Renal Cell Carcinoma (RCC): Biology, Biomarkers, and Therapeutic Opportunities.","description":"Renal Cell Carcinoma (RCC) is a common malignancy, often diagnosed incidentally. In recent years, the prognosis of metastatic disease has been improved due to the development of immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI) as first-line treatments. However, when progression occurs, the therapeutic options are limited. Understanding crucial biological pathways could lead to a greater understanding of the natural history of the disease, which could help to overcome the mechanism of resistance and to develop new treatments. The clinical significance of homologous recombination deficiency (HRD) in RCC remains to be investigated. To improve the knowledge about this topic, we conducted a narrative review to summarize the current evidence on HRD-related variations and s","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-07-05T03:12:08.85Z","creation":"2026-07-05T03:08:26.598Z"},"accession":"S-EPMC12731853","cross_references":{"pubmed":["41440218"],"doi":["10.3390/curroncol32120690"]}}